BG9928 in Subjects With Hepatic Impairment

• Status: Completed
• Trial end date: 2009-08-01

Summary

The primary objective of the study is to evaluate the effect of hepatic function on the pharmacokinetics of a single oral dose of BG9928 in subjects with mild and moderate hepatic impairment and in subjects with normal hepatic function.

• Phase: Phase 1

Details

• Lead Sponsor: Biogen